Investments in the longevity sector have been heating up, with large-scale backing of research targeting longevity-promoting supplements, technological advancements, and novel treatments for Alzheimer’s.
High-profile events were also conducted last month, including Copenhagen’s hosting of the ARDD conference. More is still to come, with the Investor’s Conference set to take place in Gstaad this September as well as many other exciting events.
Upcoming conferences and events
Exclusive Longevity Investors Conference in Gstaad
Top investors will gather in Gstaad for what’s known as the world’s most exclusive longevity conference. Bringing together scientists, advocates and investors, the event, held in Switzerland will be attended by Aubrey de Grey, Bryan Johnson, Nir Barzilai, Brian Kennedy, among others. Tickets range from 3,600 to 5,800 Swiss francs with investors welcomed to apply for tickets here.
Longevity World Forum is back this October
Returning with its third edition this autumn, the Longevity World Forum is set to be held in Alicante, Spain and promises a hybrid experience with in-person and virtual opportunities for networking. Steve Horvath and Alexandra Stolzing will be in attendance, with Toren Finkel making the opening address. Find out more about the forum here.
HLTH 2024 comes to Vegas
This October, health is set to hit center stage in Las Vegas with the HLTH 2024 conference. Covering the world’s hottest health-related topics, including longevity, AI, and healthcare marketing, the event is set to be attended by speakers such as Johnson & Johnson CEO Joaquin Duato, Vice President of Healthcare and Life Sciences at NVIDIA Kimberly Powell, and Cleveland Clinic CEO Tom Mihaljevic. Tickets are available online.
5th TimePie Longevity Forum returns this November
Longevity enthusiasts, scientists, and investors get ready to take a piece of the TimePie as they gather for the forum’s 5th edition in Shanghai. The event will feature a line-up of international speakers, including Juan Belmonte from Altos Labs, Vera Gorbunova from the University of Rochester, and Brian Kennedy from the National University Health System, alongside prominent Chinese experts like Yu-Xuan Lyu from the Southern University of Science and Technology. Tickets for the November 1-3 event are available online.
Tech breakthroughs & new research
Improving hair loss through biotech
Yuva Biosciences has partnered with Elevai Labs to develop new hair loss prevention technology. Recently, the companies filed a joint patent to protect their hair- and scalp-enhancing technology. Yuva’s Y100 mitochondrial technology and Elevai’s exosome-based treatments were combined to address hair loss in the creation of the S-Series Root Renewal System. This latest partnership marks a new stage in longevity solutions that focus on both internal and external signs of aging.
Launch of new digital health platform for longevity
Ciba Health, a digital healthcare company, has just announced the launch of a new platform designed to prevent, manage, and potentially reverse chronic health conditions. Called Thrive, the platform draws from data-driven insights combined with access to over 100 lab tests, data analytics, and continuous support from a multidisciplinary care team, including dieticians and physicians, to offer its users personalized health insights and strategies to improve their longevity by taking control of their personal health.
DAOs and communities
First 3-DAO collaboration funded: Transfidelity
76 ETH, the Ethereum network’s native currency, was raised through the collaboration of BeakerDAO, VitaDAO, and CerebrumDAO. As of August 31, this can be converted to approximately $200,000 USD. The funding, currently in the negotiation stage, is set to support a solution that aims to tackle this issue by improving protein production accuracy, potentially preventing harmful aggregates in neurodegenerative disease. Although current therapies treat symptoms, this new approach seeks to target the root causes.
Other DeSci and longevity news
Institute of Computation (IoC) launched by Altos Labs
Altos Labs has launched its Institute of Computation (IoC), aiming to leverage AI and play a pivotal role in Altos’ mission to restore cellular health. Focusing on harnessing the power of data and computational platforms for cellular rejuvenation research, the IoC complements Altos Labs’ existing Institutes of Science and Medicine. The newest edition is set to be led by Dr. Hana El-Samad and Dr. Thore Graepel, backed by an equally impressive team.
De Novo Foodlabs secures investment for new food supplement
The company formerly known as De Novo Dairy secured an investment to develop a precision-fermented, animal-free version of lactoferrin, a protein with significant health benefits, crafted using machine learning and biopharma discovery models. This latest funding round positions the company as one of the top solutions for supplements with a total investment of $4 million across various funding rounds.
Vandria receives backing from Hevolution Foundation and Dolby Family Ventures
In a Series A funding round, which garnered investments of $30.7 million, Vandria, a biotech focusing on mitochondrial therapeutics has received backing from Hevolution Foundation and Dolby Family Ventures. The latest round will go towards supporting the development of VNA-318, a therapy targeting neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, supporting clinical trials and future initiatives.
$16 million in funding for metabolic disease
Ambrosia Biosciences, a biotech startup, has just announced the successful closing of a Series A funding round valued at $16 million. The investment, led by BVF Partners and Boulder Ventures, will focus on the development of novel treatments for obesity and metabolic disorders. The proposed solution targets G-protein coupled receptors (GPCRs) to develop oral therapies similar to the popular Ozempic/Wegovy treatments for diabetes.
Openwater totals $100 million in funding for development of new solution
Having just closed a funding round valued at $54 million, bringing the total investment to $100 million, Openwater is on the path to developing a platform for disease diagnosis and treatment at a cellular level. The proposed technology utilizes infrared imaging, ultrasound, and electromagnetic fields to treat disease. At the helm of the project is ex-Google and ex-Meta executive Mary Lou Jepsen, backed by investors including Khosla Ventures and Peter Gabriel.
Social media pages to follow this month
ARDD Meeting — Get updates on the latest news from the ARDD conference.
BIO Protocol — Official X account of Decentralized Biotechnology.
Cerebrum DAO — Biotech DAO with a focus on neurodegenerative disorders.
